PMEL and neoplasm: Tumor-specific tetramer+ T cell responses reached averages of 22% for MelA (range 2–60%), 0.3% for GP100 (range 0–3%), 1.2% for TYR (range 0–8%) and 0.84% for MAGE-3 (range 0–4%) in 20 days.